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Tumor Epithelial Cell Matrix Metalloproteinase 9 (MMP-9) 
is a Prognostic Marker in Colorectal Cancer
DS Zuzga, AV Gibbons, P Li, WJ Lubbe, I Chervoneva, and GM Pitari
Colorectal cancer is the second leading cause of cancer-related mortality in 
developed nations. Mortality from colon cancer largely reflects metastasis, the 
spread of the disease to distant sites. Early diagnosis of pre-metastatic disease 
and accurate stratification of patients with metastasis is pivotal to decrease 
mortality rates from colon cancer by effectively administering surgery alone or 
with chemotherapy. However, specific pathological markers of colorectal cancer 
metastasis have not emerged. Matrix metalloproteinase 9 (MMP-9) is a key 
regulator of metastasis and a therapeutic target in colon cancer. Here, MMP-9 
overexpression in pure tumor epithelial, but nor stromal, cell populations from 
patients was associated with metastatic colorectal cancer progression as defined 
by RT-PCR and confirmed by immunostaining. Thus, tumors with increased 
MMP-9 expression compared to matched normal adjacent tissues always 
exhibited metastatic dissemination. In particular, MMP-9 overexpression in tumor 
epithelial cells, compared to normal epithelial cells, specifically predicted lymph 
node involvement. Importantly, patients with relative increase of MMP-9 levels in 
tumor epithelial cells were characterized by more advanced disease stages, with 
significantly higher proportion of regional lymph nodes harboring metastasis, 
compared to patients with a relative decrease in MMP-9 expression. Together, 
these observations suggest tumor epithelial cell MMP-9 is a novel prognostic 
marker that may be exploited for more efficient disease stage stratification and 
therapeutic regimen selection in patients with colorectal cancer.
Abstract
MMP-9 Expression Levels 
Signifies Metastasis
MMP-9 mRNA Levels in Pure Epithelial 
and Stromal Cell Populations
MMP-9 Overexpression in Tumor Epithelial 
Cells is Detected by Immunostaining
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• Increased MMP-9 expression in colorectal tumor cells is 
associated with locoregional metastatic dissemination
• MMP-9 overexpression in tumor epithelial cells is a 
prognostic indicator of metastatic colorectal cancer
• MMP-9 overexpression in colorectal tumor cell compartment 
can be detected by conventional histopathology
• Tumor epithelial cell MMP-9 represents a novel, specific 
prognostic marker and a potential therapeutic target for 
patients with colorectal cancer
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Elution
?Age (y)
Median (range) 61 (54-85)
?Gender (%)
Male 7 (63.6)
Female 4 (36.3)
?Tumor Site (%)
Colon 10 (90.9)
Rectum 1 (9.1)
?Dukes’ Tumor Stage (%)
A 1 (9.1)
B 3 (27.2)
C 5 (45.5)
D 2 (18.2)
Table I. Colorectal Cancer Patients
?Differentiation Grade (%)
Well 1 (9.1)
Moderate 7 (63.6)
Poor 3 (27.2)
?Tumor Depth (%)
Tis (carcinoma in situ) 0 (0)
T1 (limited to submucosa) 0 (0)
T2 (invading the muscularis propria) 1 (9.1)
T3 (invading the serosa) 9 (81.8)
T4 (invading adjacent organs) 1 (9.1)
?Lymph Node Metastasis (%)
Yes 7 (63.6)
No 4 (36.3)
Stage Group TNM Lymph Nodes Patient n. (%) Score
Examined (Range)
0 Tis, N0, M0 0 0 (0) 1
I T1-2, N0, M0 27 1 (9.1) 2
IIA T3, N0, M0 13-23 3 (27.3) 3
IIB T4, N0, M0 0 0 (0) 4
IIIA T1-2, N1, M0 0 0 (0) 5
IIIB T3-4, N1, M0 9-29 4 (36.3) 6
IIIC T1-4, N2, M0 13-33 3 (27.3) 7
IV+ T1-4, N0-2, M1 0 0 8
Table II. TNM-Based Stage Group & Score
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